Cite
HARVARD Citation
Lim, D. et al. (n.d.). 533TiPCANOPY-2: A phase III, placebo-controlled study of canakinumab with or without docetaxel in patients (pts) with NSCLC previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy (Ctx). Annals of oncology. p. . [Online].